
Opinion|Videos|March 21, 2025
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
5
















